EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes

Anne Bjerg Nielsen, Niklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, Rebecca C Harris, Marine Dufournet, Carsten Schade Larsen, Lykke Larsen, Lothar Wiese, Michael Dalager-Pedersen, Brian L Claggett, Kira Hyldekær Janstrup und 26 weitere

JAMA Internal Medicine · 01.03.2026 · 186 (3) · 311

DOI: 10.1001/jamainternmed.2025.7286 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2026. Verfasst von Anne Bjerg Nielsen und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Diabetes Mellitus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Influenza infection poses a substantial risk of severe complications, particularly in older adults and high-risk populations, such as individuals with diabetes. The high-dose inactivated influenza vaccine (HD-IIV) has demonstrated superior efficacy against influenza infection compared with the standard-dose inactivated influenza vaccine (SD-IIV) among adults 65 years or older. However, there is limited evidence on its effectiveness in preventing severe respiratory and cardiovascular outcomes in individuals with diabetes.

Objective

To investigate the relative vaccine effectiveness (rVE) of HD-IIV vs SD-IIV against severe respiratory and cardiovascular outcomes according to diabetes status and across diabetes subgroups. Design, Setting, and Participants This was a prespecified secondary analysis of DANFLU-2, a pragmatic, open-label, individually randomized clinical trial conducted in Denmark during the 2022/2023 to 2024/2025 influenza seasons. Adults 65 years or older were eligible for inclusion regardless of comorbidities. Data were obtained from nationwide health registries and analyzed from June to October 2025.

Interventions

Participants were randomly allocated 1:1 to receive HD-IIV or SD-IIV. Main Outcomes and Measures Outcomes included respiratory and cardiovascular hospitalizations. The potential effect modification by diabetes status and across diabetes subgroups was tested.

Results

Among 332 438 participants (mean [SD] age, 73.7 [5.8] years; 161 538 female individuals [48.6%]), 43 881 (13.2%) had diabetes. Overall, HD-IIV compared with SD-IIV was associated with reduced cardiorespiratory hospitalization, cardiovascular hospitalization, and influenza hospitalization. Effect estimates were similar for participants with and without diabetes for cardiorespiratory hospitalization (diabetes: rVE, 7.4%; 95% CI, −2.5% to 16.3%; no diabetes: rVE, 5.3%; 95% CI, 0.4%-10.0%; interaction P = .69), cardiovascular hospitalization (diabetes: rVE, 12.0%; 95% CI, −0.9% to 23.3%; no diabetes: rVE, 6.0%; 95% CI, −0.4% to 12.0%; interaction P = .38), and influenza hospitalization (diabetes: rVE, 41.6%; 95% CI, 5.0%-64.7%, vs no diabetes: rVE, 44.3%; 95% CI, 25.3%-58.7%; interaction P = .87). Duration of diabetes appeared to modify the effect of HD-IIV vs SD-IIV for cardiorespiratory hospitalization, with suggested benefit of HD-IIV in participants with diabetes duration longer than 5 years (rVE, 20.4%; 95% CI, 5.3%-33.1%), but not in those with shorter duration (rVE, −0.4%; 95% CI, −13.8% to 11.5%; interaction P = .03). Conclusions and Relevance The trial results suggest that, among adults 65 years or older, HD-IIV provided consistent benefit for cardiorespiratory, cardiovascular, and influenza hospitalizations compared with SD-IIV, regardless of diabetes status. Trial Registration ClinicalTrials.gov Identifier: NCT05517174

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanDiabetes MellitusHumansFemaleAgedMaleDenmarkHospitalizationVaccine EfficacyAged, 80 and overVaccines, Inactivated

Substanzen

Influenza VaccinesVaccines, Inactivated

Autor:innen und Institutionen

  • Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Sanofi, Morristown, New Jersey.
  • Department of Epidemiology, University of Delaware, Newark, Delaware.
  • Sanofi, Singapore.
  • Sanofi, Lyon, France.

Zitieren

APA

Nielsen, A. B., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager-Pedersen, M., Claggett, B. L., Janstrup, K. H., Bartholdy, K. V., Bernholm, K. F., Borchsenius, J. I. H., Davidovski, F. S., Davodian, L. W., Dons, M., Duus, L. S., …, & Biering-Sørensen, T. (2026). High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes. JAMA Internal Medicine, 186(3), 311. https://doi.org/10.1001/jamainternmed.2025.7286

Vancouver

Nielsen AB, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, et al. High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes. JAMA Internal Medicine. 2026;186(3):311. doi:10.1001/jamainternmed.2025.7286

BibTeX
@article{Nielsen2026,
  author = {Nielsen, Anne Bjerg and Johansen, Niklas Dyrby and Modin, Daniel and Loiacono, Matthew M and Harris, Rebecca C and Dufournet, Marine and Larsen, Carsten Schade and Larsen, Lykke and Wiese, Lothar and Dalager-Pedersen, Michael and Claggett, Brian L and Janstrup, Kira Hyldekær and Bartholdy, Katja Vu and Bernholm, Katrine Feldballe and Borchsenius, Julie Inge-Marie Helene and Davidovski, Filip Søskov and Davodian, Lise Witten and Dons, Maria and Duus, Lisa Steen and Espersen, Caroline and Fussing, Frederik Holme and Jensen, Anne Marie Reimer and Landler, Nino Emanuel and Langhoff, Adam Cadovius Femerling and Lassen, Mats Christian Højbjerg and Ottosen, Camilla Ikast and Sengeløv, Morten and Skaarup, Kristoffer Grundtvig and Pareek, Manan and Müller-Wieland, Dirk and Solomon, Scott D and Landray, Martin J and Gislason, Gunnar H and Køber, Lars and Sivapalan, Pradeesh and Martel, Cyril Jean-Marie and Jensen, Jens Ulrik Stæhr and Biering-Sørensen, Tor},
  title = {High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {3},
  pages = {311},
  doi = {10.1001/jamainternmed.2025.7286}
}
Kostenlos starten →